The Difference of Grey Matter Volume Among the Patients of Schizophrenia

NCT ID: NCT05262790

Last Updated: 2022-03-02

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 253 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-06-26
• Study Completion Date: 2017-01-01

Brief Summary

Schizophrenia is a heritable complex phenotype whose symptoms can be clustered into three domains: positive symptoms, negative symptoms and cognitive impairments. Constellations of negative symptoms in SCZ are composed of diminished motivation and pleasure, such as asociality, anhedonia, and avolition, or diminished expressivity such as blunted affect and alogia. Negative symptoms are associated with decreased quality of life and poor functional outcomes. Although antipsychotics are generally effective on positive symptoms, they are poorly effective on negative symptoms Currently, there are no licensed targeted medications for negative symptoms. In view of these problems, considerable interest in identifying new treatment targets for negative symptoms has grown over the past decade. Despite intense efforts in brain imaging that have opened new opportunities for addressing these issues, the neurobiological mechanism of negative symptoms remains unclear.

Structural brain measures from magnetic resonance imaging (MRI) are highly heritable and representatively have high reproducibility and low measurement error. Prior neuroimaging researches have consistently shown neuroanatomical abnormalities in the brains of individuals with SCZ, with the most robust and consistent group-level structural differences in widespread reduced volumes of hippocampal thalamus, amygdala and nucleus accumbens. SCZ have been associated with widespread structural brain abnormalities, but results from neuroimaging studies have been inconsistent.

Detailed Description

Schizophrenia (SCZ) is a heritable complex phenotype whose symptoms can be clustered into three domains: positive symptoms, negative symptoms and cognitive impairments. Constellations of negative symptoms in SCZ are composed of diminished motivation and pleasure, such as asociality, anhedonia, and avolition, or diminished expressivity such as blunted affect and alogia. Negative symptoms are associated with decreased quality of life and poor functional outcomes. Although antipsychotics are generally effective on positive symptoms, they are poorly effective on negative symptoms Currently, there are no licensed targeted medications for negative symptoms. In view of these problems, considerable interest in identifying new treatment targets for negative symptoms has grown over the past decade. Despite intense efforts in brain imaging that have opened new opportunities for addressing these issues, the neurobiological mechanism of negative symptoms remains unclear.

Structural brain measures from magnetic resonance imaging (MRI) are highly heritable and representatively have high reproducibility and low measurement error. Prior neuroimaging researches have consistently shown neuroanatomical abnormalities in the brains of individuals with SCZ, with the most robust and consistent group-level structural differences in widespread reduced volumes of hippocampal thalamus, amygdala and nucleus accumbens. SCZ have been associated with widespread structural brain abnormalities, but results from neuroimaging studies have been inconsistent.

Conditions

Schizophrenia; Neuroimaging; Cognitive Dysfunction

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

PNS group

The patients with prominently negative symptoms (PNS) had a greater score on the negative than on the positive subscale of the PANSS, a negative symptoms score \> 20, and at least one of items from PANSS negative symptoms scale ≥ 4 points

This is not an intervention study

Intervention Type: OTHER

PPS group

The patients with predominantly positive symptoms (PPS) had a greater score on the positive than on the negative subscale of the PANSS

This is not an intervention study

Intervention Type: OTHER

Control

Healthy control

This is not an intervention study

Intervention Type: OTHER

Interventions

This is not an intervention study

Intervention Type: OTHER

This is not an intervention study

Intervention Type: OTHER

This is not an intervention study

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• All the patients satisfied the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-Ⅳ) diagnostic criteria for schizophrenia or schizophreniform disorder.
• Women and men
• 18 to 60 years of age
• Able and willing to provide written informed consent; and willing to commit to the study protocol
• Able to read, speak, and understand Chinese

Exclusion Criteria

• (i) were <18 years or >60 years
• (ii) psychotic patients in unstable clinical condition (e.g., being aggressive and uncooperative)
• (iii) had major neurological or other psychiatric disorders, or significant medical condition including neurological disease, severe cardiovascular, hepatic, renal diseases
• (iv)had MRI abnormalities, or had MRI contraindications.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Mental Health Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

GMV-2013

Identifier Type: -

Identifier Source: org_study_id